Zamjena doksorubicina etopozidom u liječenju limfoma by Terry, Meredith Olivia
 
 
UNIVERSITY OF ZAGREB 
SCHOOL OF MEDICINE 
 
 
 
Meredith Terry 
 
 
 
 
 
 
 
 
Substitution of Doxorubicin with Etoposide in 
the Treatment of Lymphomas  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GRADUATE THESIS 
 
 
 
 
 
 
Zagreb, 2017
i 
 
 
This graduate thesis was made at the Department of Hematology at KBC Zagreb 
mentored by Prof. dr. sc. Igor Aurer and was submitted for evaluation in the 
2016/2017 academic year.  
  
ii 
 
List of Abbreviations 
aaIPI age-adjusted International Prognostic Index 
ABVD doxorubicin, bleomycin, vinblastine and dacarbazine 
BEACOPP 
bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, 
procarbazine and prednisone 
CT Computed tomography 
CTCAE Common Terminology Criteria for Adverse Events 
DLBCL Diffuse large B-cell lymphoma 
ECOG Eastern Cooperative Oncology Group 
GCB Germinal Center B-Cell 
HL Hodgkin lymphoma 
IPI International Prognostic Index 
LDH lactate dehydrogenase 
NHL Non-Hodgkin lymphoma 
PET Positron-emission tomography 
PTCL peripheral T-cell lymphoma 
R-CEOP Rituximab, cyclophosphamide, etoposodie, vincristine and predisone 
R-CHOP 
Rituximab, cyclophosphamide, doxorubicin, vincristine and 
prednisone 
SIADH Syndrome of inappropriate antidiuretic hormone secretion 
WHO World Health Organization 
  
iii 
 
List of Tables & Figures 
Table 1: Ann Arbor Staging ........................................................................................ 2 
Table 2: ECOG performance status scale .................................................................. 2 
Table 3: Factors used to determine IPI and aaIPI ...................................................... 5 
Table 4: Cheson Criteria for evaluating treatment response ...................................... 8 
Table 5: Patient demographics ................................................................................ 13 
Table 6: Prognostic factors ...................................................................................... 14 
Table 7: Pathohistological subtype of DLBCL .......................................................... 15 
Table 8: Patient outcomes ....................................................................................... 15 
Figure 1: Final response achieved ........................................................................... 16 
Figure 2: Kaplan Meier overall survival analysis ...................................................... 17 
Figure 3: Progression-free survival .......................................................................... 17 
Table 9: Median survival and log-rank results for overall survival compared to test 
variables ................................................................................................................... 18 
Figure 4: Overall survival according to sex .............................................................. 19 
Figure 5: Overall survival according to age .............................................................. 19 
Figure 6: Overall survival according to stage ........................................................... 20 
Figure 7: Overall survival according to ECOG ......................................................... 20 
Figure 8: Overall survival according to presence of B symptoms ............................ 21 
Figure 9: Overall survival according to extent of extranodal localization ................. 21 
Figure 10: Overall survival according to LDH .......................................................... 22 
Figure 11: Overall survival according to beta-2 microglobulins ................................ 22 
Figure 12: Overall survival according to IPI score ................................................... 23 
Figure 13: Overall survival in DLBCL patients according to cell of origin ................. 23 
Figure 14: Overall survival according to B or T cell lymphoma ................................ 24 
Table 10: Toxicities .................................................................................................. 25 
 
 
  
iv 
 
Table of Contents 
1. Summary ................................................................................................................. v 
2. Sažetak ................................................................................................................... vi 
3. Preface ................................................................................................................... 1 
4. Hypothesis ............................................................................................................ 10 
5. Objectives ............................................................................................................. 11 
6. Patients and Methods ........................................................................................... 12 
7. Results .................................................................................................................. 13 
8. Discussion ............................................................................................................ 26 
9. Conclusions .......................................................................................................... 28 
10. Acknowledgements............................................................................................. 29 
11. References ......................................................................................................... 30 
12. Biography ........................................................................................................... 33 
 
  
v 
 
1. Summary 
Title: Substitution of Doxorubicin with Etoposide in the Treatment of Lymphomas 
Author: Meredith Olivia Terry 
 
Purpose 
 This study set out to examine 
the survival and progression-free 
outcomes in aggressive lymphoma 
patients receiving (R)CEOP therapy 
due to contraindications for 
anthracycline therapy. Toxicities that 
developed were also evaluated and 
reported.  
Patients & Methods 
 Hospital records were searched 
for patients who received (R)CEOP in 
>50% of chemotherapy cycles. A total 
of 44 patients were included from KBC 
Zagreb, with 33 B cell lymphoma and 
11 T cell lymphoma patients. Data was 
analyzed to evaluate survival, risk 
factors, and toxicities.  
Results 
 Patients were followed up a 
median of 30.3 months. The 5 year 
overall survival rate was approximately 
48%, and event-free survival 40%. It 
was found that elevated LDH at 
diagnosis and age >70 years are poor 
prognostic factors, having a statistically 
significant correlation to poorer overall 
survival. All other risk and prognostic 
factors were not found to have a 
statistically significant impact on 
survival. The most commonly 
encountered toxicities were cytopenias 
and infections (34% and 34%).  
Conclusion 
 (R)CEOP therapy is generally 
well-tolerated in patients with co-
morbidities that preclude traditional 
anthracycline therapy. Elevated LDH 
and advanced age are poor prognostic 
factors for survival. This study found no 
statistically significant difference 
according to cell of origin in DLBCL 
patients and survival outcomes. 
Keywords: diffuse large B-cell 
lymphoma, CEOP, aggressive 
lymphoma treatment 
 
 
  
vi 
 
2. Sažetak 
Titula: Zamjena doksorubicina etopozidom u liječenju limfoma 
Autor: Meredith Olivia Terry 
Cilj 
Ovo istraživanje ispitalo je 
ukupno preživljavanje i preživljavanje 
bez događaja bolesnika s agresivnim 
limfomima koji su primali (R)CEOP 
terapiju zbog kontraindikacija za 
liječenje antraciklinima. Ispitana je i 
toksičnost ovog protokola. 
Bolesnici i metode 
 Iz bolničkih povijesti bolesti su 
identificirani bolesnici koji su primali 
(R)CEOP u >50% ciklusa 
kemoterapije. U istraživanje je 
uključeno ukupno 44 bolesnika 
liječenih u  KBC Zagrebu, 33 s B-
staničnim i 11 s limfomima T stanice.  
Na temelju prikupljenih podataka 
analizirani su preživljavanje, čimbenici 
rizika i toksičnost. 
Rezultati 
 Medijan praćenja iznosio je 30,3 
mjeseci. Petogodišnje preživljavanje 
iznosilo je 48%, a preživljavanje bez 
događaja 40%. Povišen LDH pri 
dijagnozi i dob >70 godina bili su 
statistički značajni nepovoljni 
prognostički faktori koji su korelirali s 
lošijim preživljavanjem. Za sve ostale 
rizike i prognostičke čimbenike nije 
utvrđeno da imaju statistički značajan 
utjecaj na preživljavanje. Najčešće 
toksičnosti bile su citopenije i infekcije 
(34% i 34%). 
Zaključak 
 Bolesnici s komorbiditetima koji 
onemogućavaju uobičajeno liječenje 
antraciklinima obično dobro podnose 
(R)CEOP. Povišen LDH i starija dob su 
prediktori lošijeg ishoda. U ovoj studiji 
nismo našli da postoji statistički 
značajna razlika u preživljavanju 
između bolesnika s DLBCL različitog 
staničnog porijekla. 
Ključne riječi: difuzni B-velikostanični 
limfom, CEOP, liječenje agresivnog 
limfoma
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3. Preface 
Introduction 
Lymphomas are a group of 
malignant diseases originating from 
lymphocytes. These illnesses can have 
a wide range of presentations, with a 
multitude of subtypes and prognoses. 
Even with similar histological findings, 
the symptoms and aggressiveness of 
the lymphoma can differ significantly. 
Several different classification methods 
have developed over the years, with 
the most frequently used being that 
created by the World Health 
Organization (WHO). Regarding 
staging, the Ann Arbor system is most 
common. Patients are also typically 
evaluated according to various 
prognostic indices, such as the 
International Prognostic Index (IPI) for 
NHL. Treatment depends on the 
histological subtype and stage, but 
generally involves application of a 
chemotherapeutic protocol with or 
without the addition of surgical 
intervention or radiotherapy. There are 
also a wide range of modifications to 
standard therapy that have been 
developed and are undergoing 
research to take into account co-
morbidities present in patients, age, 
and other factors that could affect 
prognosis. The remainder of this 
section will go into greater detail 
explaining the classification and 
staging of lymphomas, commonly used 
prognostic indicators, and the 
therapeutic approach to lymphomas. 
The focus of this paper is on a specific 
subset of lymphoma patients with 
contraindications to a certain 
chemotherapeutic agent, so 
information relevant to this focus will 
also be included, particularly in the 
section on treatment modalities.  
Classification of Lymphomas 
Traditionally, lymphomas are 
divided in two primary categories: 
Hodgkin lymphoma (HL) and non-
Hodgkin lymphoma (NHL). These 
malignancies can also be divided 
according to cellular origin, with the 
WHO being based on this distinction 
(1). The most recently updated WHO 
classification was published in 2016, 
and forms the basis of classification for 
most clinicians. This divides 
lymphomas into mature B-cell 
neoplasms, mature T and NK cell 
neoplasms, Hodgkin lymphoma, 
histiocytic and dendritic cell 
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neoplasms, and post-transplantation 
lymphoproliferative disorders (1). An 
additional helpful classification is 
dividing lymphomas into indolent and 
aggressive based on the behavior of 
the disease and overall outcomes 
(2,3).,Yet another descriptive 
classification is based on initial location 
of presentation, such as central 
nervous system (CNS) involvement. A 
combination of these classification 
systems is typically used, with the 
WHO classification forming the 
backbone and understanding if the 
lymphoma is indolent or aggressive to 
guide therapy choice. 
Most lymphoma subtypes can 
be additionally subdivided according to 
pathological, genetic or other 
characteristics. The most frequent 
aggressive lymphoma is diffuse large 
B-cell lymphoma (DLBCL). Using gene 
expression profiling this lymphoma can 
be divided into Germinal Center B-cell 
(GCB) and non-GCB subtypes. The 
original study demonstrated that the 
former has a better prognosis (4–7). 
Since gene expression profiling is 
complicated and expensive, it is not 
appropriate for routine clinical practice. 
Numerous attempts have been made 
to replicate this classification using 
immunohistochemistry (IHC), with 
Hans’ algorithm being used most 
frequently (4). Despite the fact that the 
prognostic value of this classification 
using IHC remains doubtful, the WHO 
classification asks for routine subtyping 
of DLBCL tumors into these two 
categories. 
Lymphoma Staging 
 Staging is a crucial part of the 
diagnostic procedure in all malignant 
diseases for several reasons, including 
therapy selection, predicting prognosis, 
and stratifying patients for research 
and quality assessment (8). The Ann 
Arbor system is used for anatomic 
staging of lymphomas on a scale of I to 
IV, with IV being the most advanced 
and generally having the poorest 
prognosis. It was originally developed 
for staging of Hodgkin lymphoma, but 
has also become generally accepted 
for non-Hodgkin lymphoma as well (8). 
A table describing the modified Ann 
Arbor staging system can be found 
below in 
Table 1. Tever greater than 38 degrees 
Celsius, drenching sweats, and weight 
loss of greater than 10% over a six 
month period are the so-called “B 
symptoms.”  
Table 1: Ann Arbor Staging (8) 
Stage Features 
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I Involvement of a single lymph node region or lymphoid 
structure 
II Involvement of two or more lymph node regions on the same 
side of the diaphragm 
III Involvement of lymph regions or structures on both sides of 
the diaphragm 
IV Involvement of extranodal site(s) beyond that designated E 
Additions: 
     A 
     B 
 
 
     E (for stages I-III) 
 
No symptoms 
Fever (>38º C), drenching sweats, weight loss (10% body 
weight over 6 months 
 
Involvement of a single extranodal site contiguous or 
proximal to known nodal site 
 
 
Prognostic Indicators 
 There are several prognostic 
indices that have been developed to 
predict outcomes in patients with 
lymphoma. The most widely used in 
NHL is the International Prognostic 
Index (IPI) (9). Five factors are 
included in this index to form a 
predicted prognosis. These include 
stage, LDH level, number of extranodal 
disease sites involved, age, and 
performance status. The Eastern 
Cooperative Oncology Group (ECOG) 
performance status is given below in  
Table 2. The age-adjusted index is a 
simplified version of IPI used to 
compare patients within the same age 
group (9). These indices have 
demonstrated their usefulness in 
predicting overall outcomes, and are 
easy to use from a clinical perspective. 
Factors used in both IPI and aaIPI can 
be seen below in   
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Table 3.  
Table 2: ECOG performance status scale (10) 
Grade Performance Description  
0 Fully active, able to carry on all pre-disease performance without 
restriction 
1 Restricted in physically strenuous activity but ambulatory and able to 
carry out work of a light or sedentary nature 
2 Ambulatory and capable of all self-care but unable to carry out any 
work activities; up and about more than 50% of waking hours 
3 Capable of only limited self-care; confined to bed or chair more than 
50% of waking hours 
4 Completely disabled; cannot carry on any self-care; totally confined to 
bed or chair 
5 Dead 
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Table 3: Factors used to determine IPI and aaIPI (9) 
Parameter IPI Score aaIPI Score 
Age > 60 years 1 n/a 
ECOG 2-4 1 1 
Stage III-IV 1 1 
Elevated LDH 1 1 
>1 Extranodal site 1 not considered 
Interpretation 
 
Low risk: 0-1 
Low intermediate risk: 2 
High intermediate risk: 3 
High risk: 4-5 
Low risk: 0 
Intermediate risk: 1 
High risk: 2-3 
  
These two clinical indices have 
been widely used, particularly in diffuse 
large B-cell lymphomas (DLBCL). 
Other factors can be used for 
predicting outcome and treatment 
response in DLBCL, including looking 
at various pathological subtypes. As 
previously mentioned, the non-GCB 
subtype was in some series associated 
with a poorer outcome. Other 
molecular markers, such as MYC and 
BCL2, are under investigation to 
determine usefulness in providing a 
prognosis for patients, and will likely 
play a greater role as additional data 
on these markers becomes available 
(11). 
In T-cell lymphoma, there is less 
consensus regarding the most 
appropriate prognostic index. Besides 
IPI, different prognostic indices have 
been proposed for various subtypes of 
T-cell lymphomas. For peripheral T-cell 
lymphomas (PTCL), four indices have 
been used and compared: IPI, 
Prognostic index for T-cell lymphoma 
(PIT), International peripheral T-cell 
lymphoma project score (IPTCLP) and 
modified Prognostic index for T-cell 
lymphoma (mPIT) (12,13). It has been 
found that IPI was best for predicting 
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complete remission, while IPTCLP was 
best for predicting overall survival (12). 
IPTCLP uses age, ECOG performance 
status, and platelet count as prognostic 
factors.  
IPI is easy to use and widely 
accepted and is therefore frequently 
used in all NHL types.  
Lymphoma Treatment 
As with many malignancies, 
lymphoma treatment centers on 
combining various therapeutic 
modalities to achieve the greatest anti-
tumor effect without causing excessive 
damage to healthy tissues. The basis 
for most aggressive lymphoma 
treatment is centered on a combination 
of several chemotherapeutic drugs. 
This can be combined with 
immunotherapy, radiation, surgical 
interventions, and stem cell transplant, 
depending on the patient and type of 
lymphoma being considered, to 
achieve the best overall outcome. The 
typical chemotherapeutic protocol for 
HL is doxorubicin, bleomycin, 
vinblastine and dacarbazine (ABVD) in 
the United States, while bleomycin, 
etoposide, doxorubicin, 
cyclophosphamide, vincristine, 
procarbazine and prednisone 
(BEACOPP) is frequently used in 
Europe. On the other hand, NHL is 
typically treated with 
cyclophosphamide, doxorubicin, 
vincristine, and prednisone (CHOP), 
with or without rituximab depending on 
the cellular origin of the lymphoma. 
These regimens form the basis for 
most lymphoma treatment, with patient 
factors dictating modifications of these 
protocols. This paper primarily focuses 
on NHL patients with cardiac 
comorbities and contraindications to 
doxorubicin treatment. 
Treating lymphomas in patients 
with cardiac disease can prove 
particularly challenging. The primary 
concern of the CHOP regimen in NHL 
patients is the cardiotoxicity of the drug 
doxorubicin, a member of the 
anthracycline class of 
chemotherapeutic drugs. 
Anthracyclines exert their effect 
through four mechanisms: inhibition of 
topoisomerase II, intercalation with 
DNA and subsequent blockage of DNA 
& RNA synthesis, generation of free 
radicals, and altering the fluidity and 
ion transport of cell membranes (14). 
As mentioned, anthracyclines are 
cardiotoxic, with both acute and 
chronic forms of this toxicity present. 
Several studies have investigated the 
development of cardiotoxicity in 
patients with aggressive lymphoma 
receiving CHOP, and it is well-
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documented (15,16). It is therefore 
inappropriate to prescribe the 
traditional CHOP regimen to patients 
with cardiac disease, and alternative 
regimens have been explored for this 
patient population. 
There are several treatment 
options that have been investigated in 
patients with aggressive lymphoma 
and a contraindication to anthracycline 
use. These include simply removing 
doxorubicin from the (R)CHOP 
protocol, replacing doxorubicin with 
etoposide, replacing doxorubicin with 
mitoxantrone, using liposome-
encapsulated doxorubicin, substituting 
procarbazine for doxorubicin, 
continuously infusing doxorubicin, or 
using bendamustine-R (17). Replacing 
doxorubicin with etoposide, with 
patients then receiving 
cyclophosphamide, etoposide, 
vincristine, and prednisone (CEOP), 
has shown some success (18). 
Etoposide, although from a different 
class of chemotherapeutic agents, has 
a similar primary mechanism of action. 
It works by inhibiting topoisomerase II, 
like doxorubicin (14). Due to this effect, 
it was postulated that this would be an 
appropriate substitute drug that would 
ideally lead to similar survival and 
progression outcomes. Several 
regional centers have evaluated the 
effects of substituting etoposide for 
doxorubicin when doxorubicin is 
contraindicated, and there have been 
mixed results (18–20). In some series 
the non-GCB DLBCL subgroup of 
patients responded worse to R-CEOP 
than the GCB subgroup (19). There 
are therefore many factors to consider 
when selecting a specific therapeutic 
regimen for a patient with aggressive 
lymphoma.  
 
Treatment Outcomes 
Overall response to treatment 
can be classified according to several 
different criteria. The most widely used 
was developed by Cheson and was 
updated in 2008 (21). In general, 
treatment response can be classified 
into five primary categories: complete 
remission, partial remission, stable 
disease unable to evaluate, and 
progressive disease or non-responsive 
(22). This classification is based on 
imaging such as PET and CT scanning 
to determine response. In lymphoma 
patients, response is often evaluated 
when half of chemotherapy cycles 
have been administered, and repeated 
when all cycles are finished.  
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Table 4: Cheson Criteria for evaluating treatment response (23) 
Treatment Outcome 
Description 
Complete Remission (CR)  Nodes returned to normal (if GTD >15 mm 
before therapy, GTD now ≤15 mm; if GTD 11-15 
and SA >10 mm before therapy, SA now ≤10 
mm) 
 All (non-nodal) target lesions completely 
resolved 
Partial Remission (PR)  SPD of target lesions decreased ≥50% from 
baseline 
 Spleen and liver nodules regress by 50% in 
SPD or single lesion in GTD 
 
Progressive Disease (PD)  SPD increase ≥50% from nadir (smallest value 
seen during trial) 
 in nodal target lesions overall  
 or in any single nodal target  
o A node with SA <10 mm must grow ≥50 % 
and to ≥15 x 15 mm or  >15 mm 
o A node with SA >10 mm must increase 
≥50% in GTD 
 or in non-nodal target lesions overall (e.g . 
liver/spleen nodules selected as target lesion 
Stable Disease (SD)  not enough shrinkage for PR 
 not enough growth for PD 
Unable to Evaluate (UE)  One or more lesions cannot be seen 
o This is most commonly caused by inadequate 
coverage 
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Treatment Toxicities 
 Chemotherapeutic regimens 
have well-documented toxicities. The 
risk of cardiotoxicity with CHOP-based 
regimens was outlined above. 
Cyclophosphamide is typically 
associated with nausea, vomiting, 
cytopenias, alopecia, and occasionally 
cystitis (14). Vincristine has potential 
adverse effects including neurotoxicity 
(especially peripheral neuropathy), 
paralytic ileus, myelosuppression, 
alopecia, and possibly SIADH (14). 
Prednisone has a plethora of potential 
side effects, including metabolic effects 
like fat redistribution, increased 
appetite, insomnia, impaired wound 
healing, muscle wasting, peptic ulcers, 
and impaired immune response (14). 
Etoposide is typically associated with 
nausea, vomiting, hypotension, 
alopecia, and myelosuppression (14). 
Rituximab is rarely associated with 
significant side effects; there is 
occasionally a transfusion-type 
reaction including rash development 
(14). Alopecia, nausea, vomiting, and 
cytopenia are commonly encountered 
side effects in patients receiving CHOP 
or CEOP therapy. Toxicities can be 
classified and graded according to the 
Common Terminology Criteria for 
Adverse Events (CTCAE) developed 
by the U.S. National Institute of Health 
(24).   
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4. Hypothesis 
 The hypothesis of this study is 
that (R)CEOP is a valid 
chemotherapeutic regimen in treating 
patients with NHL, with good 
progression-free and overall survival 
outcomes. It is also predicted that 
there will not be significant excess 
toxicity associated with this protocol. 
Lastly, it is hypothesized that (R)CEOP 
treatment will have better outcomes in 
the GCB subtype of DLBCL patients in 
comparison to the non-GCB subtype. 
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5. Objectives 
 The objectives of this study are 
to examine the progression-free and 
overall survival of patients with 
aggressive NHL receiving (R)CEOP 
therapy. The toxicities of this protocol 
will also be examined to determine 
their severity. Finally, since it has been 
suggested that patients with non-GCB 
DLBCL fare worse with R-CEOP 
therapy than those with the GCB 
subtype, this study sets out to 
determine if there is a difference in 
response to R-CEOP therapy between 
these two subtypes. Additional factors, 
such as the International Prognostic 
Index (IPI), will also be considered 
when looking at treatment outcomes.  
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6. Patients and Methods 
 In order to examine the effects 
of (R)CEOP treatment in lymphoma 
patients, archival data was collected 
retrospectively from hospital 
documentation from 2009 to present. 
Patients were selected if they received 
>50% of chemotherapeutic cycles 
according to CEOP or R-CEOP 
protocol for de novo B or T cell 
lymphoma. A total of 44 patients 
fulfilled these criteria, with 33 B cell 
and 11 T cell lymphoma patients. One 
patient received two cycles of R-COP 
prior to starting R-CEOP, three 
patients were first started on R-CHOP 
then converted to R-CEOP, and one 
patient received CHEOP prior to 
starting CEOP. Patients received a 
median of eight cycles of (R)CEOP 
(range 1-8). Thirteen patients received 
radiation therapy (30%), and four 
patients received intrathecal 
methotrexate (9%).  
Descriptive statistics for the 
patient population can be found in the 
following section. The statistical 
analyses were performed using the 
program Statistica. Kaplan-Meier 
survival analysis was performed to 
examine the overall survival and 
progression-free survival outcomes. 
Additional log-rank tests have been 
performed to examine the effect of 
several variables on outcomes, 
including LDH, age, gender, IPI score, 
ECOG status, and cellular origin in 
DLBCL. These results can also be 
found in the following section. 
Toxicities were also examined and 
graded according to the Common 
Terminology Criteria for Adverse 
Events (CTCAE) (24).  
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7. Results 
Descriptive Statistics 
 Based on the criteria outlined in 
the previous section, 44 patients were 
included in this study. There was 
roughly equal distribution of male and 
female patients, with 52% male and 
48% female. The median age was 
76.5, with patient ages ranging from 58 
to 87. The majority of patients were 
above age 60. Overall, 86% of patients 
were Stage III or IV, 55% had B 
symptoms, 77% had extranodal 
localization, 18% had ECOG status 3 
or 4, 57% had elevated LDH, and 66% 
had IPI score of 3-5. Additionally, 30% 
of patients also received radiation 
therapy.   
 
Table 5 provides basic descriptive data 
for patients, including sex and age 
group. This is then followed by Table 6 
and descriptive data for prognostic 
factors such as stage, ECOG 
performance status, LDH level, IPI, 
and aaIPI. Table 7 is specific for 
DLBCL patients and provides 
descriptive information regarding GCB 
vs. non-GCB status in this subgroup. 
Cell of origin information was obtained 
for 24 out of 33 (73%) DLBCL patients 
according to Hans criteria (4). Table 8 
describes final outcomes patients 
achieved.   
 
 
Table 5: Patient demographics 
Variable 
B-cell 
N = 33 (%) 
T-cell 
N = 11 (%) 
Sex 
     Male 
     Female 
 
15  (45%) 
18  (55%) 
 
8  (73%) 
3  (27%) 
Age Group 
     ≤60 
     >61 
 
2  (6%) 
31  (94%) 
 
1  (9%) 
10  (91%) 
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Table 6: Prognostic factors 
Variable 
B-cell 
N = 33 (%) 
T-cell 
N = 11 (%) 
Initial Staging 
     I  
     II 
     III 
     IV 
 
4  (12%) 
0  (0%) 
8  (24%) 
21  (64%) 
 
1  (9%) 
1  (9%) 
4  (36%) 
5  (45%) 
B Symptoms 
     Present 
     Absent 
 
19  (58%) 
14  (42%) 
 
5  (45%) 
6  (55%) 
Extranodal Localization 
     Present 
     Absent 
 
28  (85%) 
5  (15%) 
 
6  (55%) 
5  (45%) 
ECOG Status 
     1 
     2 
     3 
     4 
 
7  (21%) 
20  (61%) 
6  (18%) 
0  (0%) 
 
6  (55%) 
3  (27%) 
2  (18%) 
0  (0%) 
LDH 
     Normal 
     Elevated 
 
13  (39%) 
20  (61%) 
 
6  (55%) 
5  (45%) 
IPI 
     1 
     2 
     3 
     4 
     5 
 
3  (9%) 
5  (15%) 
7  (21%) 
11  (33%) 
7  (21%) 
 
1  (9%) 
6  (55%) 
2  (18%) 
2  (18%) 
0  (0%) 
aaIPI 
     0 
     1 
     2 
     3 
 
2  (6%) 
4  (12%) 
12  (36%) 
15  (45%) 
 
0  (0%) 
8  (73%) 
1  (9%) 
2  (18%) 
15 
 
Table 7: Pathohistological subtype of DLBCL 
Pathohistological subtype N = 33 (%) 
GCB 11  (33%) 
non-GCB 13  (39%) 
Not evaluated 8  (24%) 
 
 
Table 8: Patient outcomes 
Variable 
B-cell 
N = 33 (%) 
T-cell 
N = 11 (%) 
Final response 
     Complete remission 
     Partial remission 
     Stable disease 
     Non-responsive 
     Not evaluated/lost to follow up 
 
17  (52%) 
6  (18%) 
1  (3%) 
2  (6%) 
7  (21%) 
 
5  (45%) 
2  (18%) 
1  (9%) 
3  (27%) 
0  (0%) 
Overall survival 
     Alive 
     Dead 
 
20  (61%) 
13  (39%) 
 
6  (55%) 
5  (45%) 
Progression-free survival 
     No Progression 
     Progression 
 
27  (82%) 
6  (18%)  
 
6  (55%) 
5  (45%) 
 
 Out of a total of 44 patients, 30 
(68%) responded to treatment. Of 
these 30 patients, 22 achieved 
complete remissions, and 8 achieved 
partial remission. Two (5%) patients 
achieved stable disease, 5 (11%) 
progressed, and 7 (16%) were lost to 
follow-up or have not yet completed 
treatment and have therefore not been 
evaluated. Figure 1 displays this 
information in graphical format.  
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Figure 1: Final response achieved 
 
 
Survival Analysis & Log-Rank Tests 
 Median follow-up 30.3 months 
(The overall survival curves for each of 
these variables can also be seen 
below in Figures 4-13.  
Complete 
Remission 
50% 
Partial 
Remission 
18% 
Stable Disease 
5% 
Non-
responsive 
11% 
Not 
evaluated/Lost 
to Follow-up 
16% 
Final Response 
1 
 
Overall Survival
Complete  Censored
0 20 40 80 1001y 2y 3y 5y
Survival Time
0,0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1,0
C
u
m
u
la
ti
v
e
 P
ro
p
o
rt
io
n
 S
u
rv
iv
in
g
Figure 2), 5-year overall survival rate 
48%, median event-free survival 16.6 
months (
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Figure 3), and 5-year event-free 
survival 40%.  
 Several variables were tested to 
determine if they had a statistically 
significant influence on overall survival. 
These were: sex, age greater than or 
less than 70, stage, ECOG 
performance status, extranodal 
localization, B symptoms, LDH level, 
beta-2 microglobulins level, IPI score, 
and GCB versus non-GCB in DLBCL 
patients. According to log-rank testing 
and using a significance level of α = 
0.05, a statistically significant 
difference was observed for age at 
diagnosis (p = 0.04726) and for LDH 
level (p = 0.02706). The median 
survival in months and associated p-
vales for each of these variables can 
be seen below in Table 9. The overall 
survival curves for each of these 
variables can also be seen below in 
Figures 4-13.  
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Figure 2: Kaplan Meier overall survival analysis 
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Figure 3: Progression-free survival   
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Table 9: Median survival and log-rank results for overall survival in relation to tested 
variables 
Variable 
50th percentile (median) 
months 
Log-rank test p-value 
α = 0.05 
Sex 
(Figure 4) 
Male = 27.1 
Female = N/A 
p = 0.70942 
Age 
(Figure 5) 
≤70 = 53.1 
>70 = 16.4 
p = 0.04726 
Stage 
(Figure 6) 
I or II = 9.7 
III or IV = 28.6 
p = 0.65654 
ECOG 
(Figure 7) 
1 or 2 =41.9 
3 or 4 =12.2 
p = 0.06376 
B symptoms 
(Figure 8) 
Present =15.7  
Absent = 28.1 
p = 0.69666 
Extranodal localization 
(Figure 9) 
Present = N/A 
Absent = 20.4 
p = 0.51793 
LDH 
(Figure 10) 
Normal = 37.6 
Elevated =12.5 
p = 0.02706 
Beta-2 microglobulins 
(Figure 11) 
Normal = 40.6 
Elevated = 11.8 
p = 0.07871 
IPI 
(Figure 12) 
1 or 2 = 29.4 
3, 4 or 5 = 19.0 
p = 0.60954 
GCB vs. non-GCB 
(Figure 13) 
GCB = N/A 
non-GCB = 28.6  
p = 0.21112 
B cell vs. T cell 
(Figure 14) 
B cell = 46.0 
T cell = 16.3 
p = 0.12388s 
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Figure 4: Overall survival according to sex 
Overall Survival according to Age
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Overall Survival according to Stage
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Figure 6: Overall survival according to stage 
Overall Survival according to ECOG
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Overall Survival according to B symptoms
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Figure 8: Overall survival according to presence of B symptoms 
Overall Survival according to Extranodal Localization
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Overall Survival according to LDH
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Figure 10: Overall survival according to LDH  
Overall Survival according to beta2 microglobulins
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Figure 11: Overall survival according to beta-2 microglobulins 
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Overall Survival according to IPI
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Figure 12: Overall survival according to IPI score 
Overall Survival
GCB vs. non-GCB
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Figure 13: Overall survival in DLBCL patients according to cell of origin 
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Overall Survival according to B or T cell lymphoma
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Figure 14: Overall survival according to B or T cell lymphoma 
 
Toxicities 
 The most common toxicities 
were cytopenia and febrile 
neutropenia. Twenty-one patients were 
hospitalized due to unwanted toxicity, 8 
patients developed some type of 
cardiovascular toxicity that was 
primarily thromboembolic in nature, 
and 15 patients developed infectious 
complications. Overall, 8 patients died 
from treatment-related causes, giving a 
treatment-related mortality of 18%. 
Other toxicities experienced by 
patients include nausea, constipation, 
neuropathy, hyponatremia, fatigue, 
hypogammaglobulinemia, edema, 
dysphagia, and pleural effusion. 
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Table 10: Toxicities 
Toxicity 
Number of Patients 
N = 44 (%) 
Hematologic toxicity grade 3 or 4 15  (34%) 
Infectious complications grade 3 or 4 15  (34%) 
Cardiovascular toxicity grade 3 or 4 
(including thromboembolic events) 
8  (18%) 
Hospitalization 21  (48%) 
Treatment-related mortality 8  (18%) 
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8. Discussion 
This study set out to examine 
the outcomes of patients receiving 
(R)CEOP treatment, looking at various 
prognostic factors to determine effect 
on overall survival, and to report 
toxicities that developed in this group. 
Of the prognostic factors considered, 
only elevated LDH at time of diagnosis 
and age >70 were found to have a 
statistically significant impact on 
survival outcomes. Of note, there was 
no statistically significant difference 
when considering cell of origin (GCB 
vs. non-GCB) in DLBCL patients. This 
is different than most other published 
study findings. It is possible that the 
number of patients included in cell of 
origin analysis was not large enough. 
Of the 33 patients with DLBCL, only 24 
had cell of origin data available. If more 
patients were included, or a larger 
number of patients had cell of origin 
data available, this may change the 
results. Regardless, this study 
indicates that the R-CEOP treatment 
outcomes in patients with non-GCB 
DLBCL are not statistically significantly 
worse than those of GCB patients.  
Patients who receive (R)CEOP 
rather than (R)CHOP generally do so 
because of pre-existing cardiac co-
morbidities, which is also often 
associated with advanced age. For this 
reason, it is typically expected that 
these patients have worse overall 
outcomes in comparison to patients 
without these co-morbidities. When 
comparing the results of this study to 
that of other published findings, such 
as those published by Rashidi et. al. 
(19), the 2 year overall survival (54% 
vs. 59%) and progression-free survival 
(49% vs. 49%) are similar. However, 
the study conducted by Rashidi et. al. 
only included DLBCL patients, while 
this research also included T cell 
lymphoma patients. Thirty patients 
(68%) achieved response to therapy, 
with 22 (50%) achieving complete 
remission.  
Several toxicities developed in 
the patients included in the study. 
Hematologic and infectious 
complications are frequent in this 
treatment regimen, as described in the 
preface. As this treatment protocol is 
intended to reduce cardiac toxicity, it is 
important to note that only one patient 
developed a myocardial infarction, 
which appeared almost two years after 
treatment was completed. Other 
cardiovascular toxicities were 
thromboembolic in nature, including 
deep venous thrombosis and 
pulmonary emboli. As the primary 
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indication for CEOP over CHOP is 
cardiac co-morbidity and concern over 
anthracycline impact, this is a positive 
result.  
To obtain a better perspective 
on how effective (R)CEOP is in treating 
aggressive lymphoma patients, it 
would be appropriate to create a 
control group of comparable (R)CHOP 
patients and evaluate the differences in 
outcome when controlling for age, sex, 
and socioeconomic status. A 
sufficiently large sample size may be 
difficult to achieve if only including 
patients from one hospital center, and 
data from several centers could be 
combined to achieve a more robust 
result. Toxicities that develop during 
and after treatment could also be 
considered, and this would provide 
further information on the 
appropriateness of administering 
(R)CEOP rather than (R)CHOP in 
specific patient subgroups. Comparing 
(R)CEOP to other alternative regimens 
for aggressive lymphoma patients with 
anthracycline contraindications, such 
as bendamustine, replacing 
doxorubicin with procarbazine, 
continuously infusing doxorubicin, or 
using liposome-enacpsulated 
doxorubicin, would allow further 
conclusions to be drawn about what is 
the most appropriate treatment to use 
in this patient subgroup. 
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9. Conclusions 
 Patients who received (R)CEOP 
at KCB Zagreb due to anthracycline 
contraindication developed minimal 
cardiac toxicity during treatment and 
68% achieved some level of response 
to therapy. In this patient population, 
elevated LDH at diagnosis and 
advanced age were negatively 
associated with survival outcomes. 
Based on these results, (R)CEOP is an 
appropriate chemotherapeutic regimen 
in aggressive NHL, including both B 
and T cell lymphomas. Additional 
studies may be performed to compare 
the patient population examined to 
those who received first line (R)CHOP 
therapy to draw further conclusions 
regarding this chemotherapeutic 
protocol.  
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